A study analyzing therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy
Latest Information Update: 10 Oct 2022
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
- Focus Therapeutic Use
Most Recent Events
- 10 Oct 2022 New trial record
- 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology